- Home
- YMAT vs GNPX Comparison
YMAT vs GNPX Comparison
Compare YMAT & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMAT | GNPX |
|---|---|---|
| Founded | 1970 | 2009 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.4M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | YMAT | GNPX |
|---|---|---|
| Price | $0.32 | $1.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.9K | ★ 302.8K |
| Earning Date | 05-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.14 |
| 52 Week High | $6.45 | $12.97 |
Technical Indicators
Market Signals| Indicator | YMAT | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 40.00 |
| Support Level | $0.31 | $0.18 |
| Resistance Level | $0.52 | $2.12 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 3.92 | 3.19 |
Price Performance
Historical ComparisonAbout YMAT J-Star Holding Co. Ltd. Ordinary Shares
J Star Holding Co Ltd is engaged in the research, development and manufacturing of carbon fiber for a wide variety of products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.